Rubius Therapeutics posts $47M loss in Q3 on increase in R&D expenses

CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company announced on Thursday. The clinical-stage biopharmaceutical company reported a loss of $26.4 million in the third quarter of 2018, or 42 cents per diluted share.   The company has a 135,000-square-foot…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -